Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Spinal Muscular Atrophy Treatment Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The spinal muscular atrophy treatment market size has experienced significant growth in recent years. It is anticipated to expand from $5.1 billion in 2025 to $5.89 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.5%. Historically, this market expansion can be linked to several factors: a limited array of therapeutic options for SMA, insufficient awareness of genetic disorders, a reliance on hospital-based treatment, a sluggish adoption rate for innovative therapies, and the absence of comprehensive early diagnosis programs.
The spinal muscular atrophy treatment market size is projected to experience substantial expansion in the coming years. It will grow to $10.38 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. This anticipated growth during the projection period can be attributed to several factors, including the advancement of gene therapies, increased funding for SMA research, expanded newborn screening programs, the proliferation of specialty clinics and at-home care options, and the incorporation of digital health and remote medical solutions. Key trends anticipated for the forecast period encompass a greater acceptance of gene therapy and SMN2-modifying treatments, an intensified emphasis on early detection and newborn screening efforts, an expansion of SMA management services through homecare and specialized clinics, the formation of more multidisciplinary care teams for SMA patients, and the seamless integration of telehealth with remote patient monitoring systems.
Get A Free Sample Report With In-Depth Market Insights:
Spinal Muscular Atrophy Treatment Market Growth Catalysts And Demand Drivers
The increasing emphasis on gene therapy is projected to boost the expansion of the spinal muscular atrophy treatment market in the future. This medical approach entails altering an individual’s genetic makeup, specifically DNA or RNA, with the aim of treating or preventing various illnesses. The heightened attention on gene therapy stems mainly from its capacity to address or resolve the fundamental cause of genetic conditions through direct modification or replacement of defective genes, providing sustained or lasting therapeutic outcomes relative to conventional therapies. Specifically, spinal muscular atrophy treatments benefit from gene therapy, exemplified by onasemnogene abeparvovec (Zolgensma), which offers a single-dose, precise method to introduce a working copy of the SMN1 gene, substantially enhancing motor capabilities and patient life quality for those with SMA. As an illustration, in January 2024, the American Society of Gene and Cell Therapy, a US-based organization focused on gene and cell therapy, reported that the volume of gene therapies undergoing Phase III trials saw a rise of 10% in the fourth quarter of 2023 when contrasted with the preceding quarter. This represented the initial such uptick recorded since the third quarter of 2022. Consequently, the increased emphasis on gene therapy is fueling the expansion of the spinal muscular atrophy treatment market.
Spinal Muscular Atrophy Treatment Market Segment Performance And Emerging Opportunities
The spinal muscular atrophy treatment market covered in this report is segmented –
1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments
2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications
2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises
3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy
4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy
Spinal Muscular Atrophy Treatment Market Trends Shaping Long-Term Demand
Leading companies in the spinal muscular atrophy treatment market are concentrating on developing innovative formulations like survival motor neuron 2 (SMN2) splicing modifier tablets to improve motor function and slow disease progression. Survival motor neuron 2 (SMN2) splicing modifier tablets are oral medications crafted to modify the splicing of the SMN2 gene, thereby enabling the production of functional SMN protein essential for motor neuron survival. These tablets aid in treating spinal muscular atrophy (SMA) by boosting the levels of full-length SMN protein, consequently enhancing muscle function and slowing the disease’s advancement. For instance, in February 2025, Genentech, Inc., a US-based biotechnology company, secured U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet, recognized as the inaugural and only non-invasive SMN2 splicing modifier tablet for SMA treatment. The Evrysdi tablet provides comparable efficacy and safety to the current oral solution, with additional benefits such as storage at room temperature and simplified administration for patients aged 2 years and older who weigh more than 44 lbs (20 kgs), offering enhanced convenience and adaptability in managing the condition.
Spinal Muscular Atrophy Treatment Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED
View The Full Spinal Muscular Atrophy Treatment Market Report:
Spinal Muscular Atrophy Treatment Market Regional Analysis And Leading Geography
North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model